Abrdn Life Sciences Investors (HQL)

$15.42

+0.04

(+0.23%)

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $15.37
    $15.56
    $15.42
    downward going graph

    0.32%

    Downside

    Day's Volatility :1.22%

    Upside

    0.9%

    downward going graph
  • $10.39
    $15.63
    $15.42
    downward going graph

    32.62%

    Downside

    52 Weeks Volatility :33.53%

    Upside

    1.34%

    downward going graph

Returns

PeriodAbrdn Life Sciences InvestorsRussel 2000Index (Russel 2000)
3 Months
18.62%
0.0%
0.0%
6 Months
12.88%
0.0%
0.0%
1 Year
14.56%
0.0%
0.0%
3 Years
-25.46%
-20.2%
-20.2%

Highlights

Market Capitalization
416.1M
Book Value
$16.13
Dividend Share
1.3
Dividend Yield
9.79%
Earnings Per Share (EPS)
1.34
PE Ratio
11.35
PEG Ratio
0.0
Profit Margin
156.45%
Operating Margin TTM
-31.63%
Return On Assets TTM
-0.32%
Return On Equity TTM
1.28%
Revenue TTM
3.5M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
7.000000000000001%
Gross Profit TTM
3.0M
Diluted Eps TTM
1.34
Quarterly Earnings Growth YOY
0.43
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Abrdn Life Sciences Investors is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
9.35%
12.88%
14.56%
-25.46%
-5.61%
Blackstone Inc
Blackstone Inc
12.77%
12.4%
33.72%
23.59%
184.25%
Kkr & Co. L.p.
Kkr & Co. L.p.
10.33%
34.54%
92.34%
88.76%
327.51%
Blackrock, Inc.
Blackrock, Inc.
6.23%
6.25%
12.57%
-4.01%
74.95%
Apollo Asset Management Inc
Apollo Asset Management Inc
3.05%
21.28%
49.39%
105.06%
236.64%
Brookfield Corp
Brookfield Corp
13.39%
14.03%
30.81%
-8.62%
40.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
11.35
11.35
0.0
0.0
0.01
0.0
0.1
16.13
Blackstone Inc
Blackstone Inc
54.02
54.02
1.75
4.55
0.19
0.09
0.02
8.9
Kkr & Co. L.p.
Kkr & Co. L.p.
25.67
25.67
1.3
4.66
0.11
0.02
0.01
24.2
Blackrock, Inc.
Blackrock, Inc.
20.53
20.53
2.46
38.23
0.15
0.03
0.02
267.04
Apollo Asset Management Inc
Apollo Asset Management Inc
13.58
13.58
1.37
7.49
0.3
0.02
0.02
23.53
Brookfield Corp
Brookfield Corp
76.42
76.42
NA
4.56
0.03
0.02
0.01
26.75
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abrdn Life Sciences Investors
Abrdn Life Sciences Investors
NA
$416.1M
-5.61%
11.35
156.45%
Blackstone Inc
Blackstone Inc
Hold
$172.6B
184.25%
54.02
20.25%
Kkr & Co. L.p.
Kkr & Co. L.p.
Buy
$105.8B
327.51%
25.67
15.64%
Blackrock, Inc.
Blackrock, Inc.
Buy
$122.7B
74.95%
20.53
32.36%
Apollo Asset Management Inc
Apollo Asset Management Inc
Buy
$68.8B
236.64%
13.58
16.23%
Brookfield Corp
Brookfield Corp
Buy
$71.2B
40.39%
76.42
1.14%

Insights on Abrdn Life Sciences Investors

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 29.56M → -225.19K (in $), with an average decrease of 100.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -11.45M → 50.25M (in $), with an average increase of 122.8% per quarter

  • Vs KKR

    In the last 1 year, Kkr & Co. L.p. has given 92.3% return, outperforming this stock by 77.7%

  • Vs APO

    In the last 3 years, Apollo Asset Management Inc has given 88.8% return, outperforming this stock by 114.3%

Company Information

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form

Organization
Abrdn Life Sciences Investors
Employees
0
CEO
Dr. Daniel R. Omstead M.S, Ph.D.
Industry
Miscellaneous

FAQs